ArticleThoracic cancer2020
Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer.
Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Evaluation of variables predicting PFT changes for lung cancer patients treated on a prospective 4DCT-ventilation functional avoidance clinical trial.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2023Trial
- Factors that Influence the Need to Start Adaptive Radiotherapy.Journal of immunotherapy and precision oncology · 2024Article
- Dosimetric comparison of four radiotherapy techniques for stage III non‑small cell lung cancer.Oncology letters · 2023Article
- Article
- Article
- Carbon Monoxide Diffusing Capacity (DLDiagnostics (Basel, Switzerland) · 2022Article
- Genetic variations in DNA repair gene NEIL1 associated with radiation pneumonitis risk in lung cancer patients.Molecular genetics & genomic medicine · 2021Article
- New developments in locally advanced nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- Re-Irradiation for Locally Recurrent Lung Cancer: A Single Center Retrospective Analysis.Current oncology (Toronto, Ont.) · 2021Article
- Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single-center retrospective analysis.Thoracic cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemoradiotherapy (CRT) is the standard treatment for patients with inoperable stage III non-small cell lung cancer (NSCLC) stage III. With a median OS beyond 30 months, adequate pulmonary function (PF) is essential to ensure acceptable quality of life after treatment. Forced expiratory volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) are the most widely used parameters to assess lung function. The aim of the current study was to evaluate dose-volume effects of accelerated high-dose radiation on PF.
methodsA total of 72 patients were eligible for the current analysis. After induction chemotherapy, all patients received dose-differentiated accelerated radiotherapy with intensity-modulated radiotherapy (IMRT-DART). PF tests were performed six weeks, three and six months after the end of radiotherapy.
resultsThe median total dose to the tumor was 73.8 Gy (1.8 Gy bid) with a size dependent range between 61.2 and 90 Gy. In the whole cohort, 321 pulmonary function tests were performed. At six months, the median FEV1 relative to baseline was 0.95 (range: 0.56-1.36), and the relative median DLCO decreased to 0.98 (range: 0.64-1.50). The correlation between V20
conclusionPatients with a V20 KEY POINTS: Significant findings: Pulmonary function after high dose irradiation decreases only moderately. FEV1 and DLCO decrease depend on V20 WHAT THIS STUDY ADDS: This study shows that high-dose irradiation delivered with intensity-modulated techniques does not impair short-term lung function even in patients with compromised respiratory capacity before treatment. This is a pre-requisite for adequate quality of life after thoraco-oncological therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.